Esra Aydemir Coban

Title: Esra Aydemir Coban: Innovator in Chemotherapeutic Agents

Introduction

Esra Aydemir Coban is a notable inventor based in Istanbul, Turkey. He has made significant contributions to the field of chemotherapeutic agents, particularly in the treatment of pancreatic cancer. His innovative approach combines existing compounds to enhance their effectiveness against cancer cells.

Latest Patents

Esra Aydemir Coban holds a patent for a chemotherapeutic agent that comprises a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate. This invention includes 2.9 mg of alexidine dihydrochloride and 2.5 mg of sodium pentaborate pentahydrate, which are combined with 0.5 ml of dimethylsulfoxide. The results of his research indicate that this combination decreases pancreatic cancer cell viability by 10% more than using alexidine dihydrochloride alone, showcasing its potential as a treatment option.

Career Highlights

Esra Aydemir Coban is affiliated with Yeditepe University, where he conducts his research and development in the field of chemotherapeutics. His work has garnered attention for its innovative approach to cancer treatment, particularly in enhancing the efficacy of existing compounds.

Collaborations

Esra collaborates with notable colleagues such as Fikrettin Sahin and Ezgi Kasikci, who contribute to his research efforts and the advancement of his inventions.

Conclusion

Esra Aydemir Coban's work in developing a novel chemotherapeutic agent represents a significant advancement in cancer treatment. His innovative approach and collaboration with esteemed colleagues highlight the importance of research in the fight against pancreatic cancer.